Takara Bio Inc is primarily active in the life sciences industry. This Japanese company specializes in the development and manufacture of biotechnology products, including genomic research tools, reagents, and systems for areas such as genetic engineering, stem cell research, and diagnostics. Takara Bio Inc's innovative solutions and advanced technologies have made significant contributions to various fields of life sciences, including academic research, pharmaceutical development, and agricultural biotechnology. As a leader in the industry, Takara Bio Inc continuously strives to advance scientific knowledge and provide cutting-edge solutions for the global life sciences community.

The main competitors of Takara Bio Inc in the market are Thermo Fisher Scientific, Bio-Rad Laboratories, and QIAGEN.

Takara Bio Inc is a leading biotechnology company based in Japan. Established in 1967, the company has a rich history and a strong background in the field. Takara Bio specializes in the development and manufacture of a wide range of innovative products and solutions for the life sciences industry. With a focus on advancing research and improving human health, Takara Bio has become synonymous with reliability and cutting-edge technology. Through its dedication to quality and customer satisfaction, the company has gained a global reputation as a trusted provider of biotechnology solutions.

Takara Bio Inc, a leading biotechnology company, has achieved several significant milestones. They developed and commercialized various innovative products and technologies for life science research, including PCR and DNA sequencing systems. Takara Bio Inc played a pivotal role in advancing genetic engineering and molecular biology techniques worldwide. Additionally, they developed advanced stem cell technologies and contributed to significant breakthroughs in regenerative medicine. Moreover, the company successfully expanded its global presence by establishing subsidiaries and collaborations in various regions. With its continuous commitment to innovation and research, Takara Bio Inc remains at the forefront of the biotechnology industry, providing valuable solutions to researchers and scientists worldwide.

Takara Bio Inc is primarily present in Japan, with its headquarters located in Kusatsu, Shiga. Apart from its domestic presence, the company also maintains a global presence with operations and subsidiaries in various countries and regions including the United States, Europe, China, and other Asian countries. Takara Bio Inc is a leading biotechnology company specializing in the development and distribution of life science research reagents, gene therapy products, and molecular diagnostics. With its extensive global reach, Takara Bio Inc continues to provide innovative solutions and contribute to advancements in the fields of genomics, stem cell research, and personalized medicine.

Takara Bio Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. With their corporate philosophy centered on contributing to society through the development of advanced technologies, Takara Bio Inc focuses on improving the quality of life and healthcare. The company aims to create value by delivering cutting-edge solutions and products that cater to diverse research needs, ranging from genetic analysis to regenerative medicine. Takara Bio Inc prioritizes customer satisfaction, sustainability, and responsible business practices, ensuring sustainable growth and development in the biotechnology industry.

Analysts currently set an average price target of 1 063,35 JPY for the Takara Bio stock (median: 800,70 JPY), implying −7,0 % versus the latest price. The consensus is based on 8 analyst ratings.

Takara Bio Analyytikkojen kursstavoitteet 2026

8 analysts currently rate the Takara Bio stock: 4 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Takara Bio to generate revenue of 49,46 Mrd. JPY and earnings per share of 39,20 JPY.

Takara Bio Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Takara Bio share trades at 6,27 EUR (1 144,00 JPY).

The Takara Bio share (4974.T) is listed on 3 stock exchanges, including: Frankfurt (TF2.F), München (TF2.MU).

Takara Bio Inc is a leading company in the field of biotechnological research and development. The company specializes in the manufacturing and marketing of high-quality biological reagents and instruments that support a variety of research applications. The business model of Takara Bio Inc is based on providing products and services that assist researchers and scientific laboratories in carrying out their critical workflows. The company offers a wide range of reagents and instruments that focus on various applications such as gene expression, genotyping, proteome analysis, and cell culture. These products are sold worldwide to a variety of customers including pharmaceutical, biotech, and diagnostic companies, as well as public and private research institutions. Takara Bio Inc also has a research and development department that develops new and innovative products to provide solutions to customers and researchers. One such innovation is the SmartChip PCR system, a fully automated instrument that processes multiple samples simultaneously and is used to analyze gene expression profiles on a single chip. Another important area of focus for Takara Bio Inc is the manufacturing of mRNA-based therapeutics, which are used to combat diseases such as cancer. The company has already achieved significant success in this regard and has formed partnerships with other companies and research institutions to further advance. Takara Bio Inc divides its business model into three main divisions. The first division deals with the sale of reagents and instruments for genomic research and cellular analysis. Here, the company offers a wide range of reagents and kits to support DNA purification, PCR products, nanopore sequencing, amplification, genotyping and labeling, as well as plasmid minipreps and RNA isolation. The second division is the therapeutics division, which focuses on mRNA-based therapeutics and customized therapeutic vaccines to keep customers at the forefront of disease fighting in the biotech industry and clinical research. Takara Bio Inc has produced innovative methods for developing vaccines against cancer and other diseases. The third division is the service-oriented application technology, which assists customers in overcoming complex research challenges. The services include customized and technically sophisticated programs such as RNA sequencing, FACS assays, and ChIP sequencing. In summary, Takara Bio Inc is a company that focuses on biotechnological research and development. The business model of Takara Bio Inc includes the manufacturing and marketing of biological reagents and instruments that can be used in both basic research and clinical research and diagnostics. The three main divisions of Takara Bio Inc are the sale of reagents and instruments for genomic research and cellular analysis, the development of mRNA-based therapeutics, and services for customized application programs. With a strong focus on quality and innovation, Takara Bio Inc drives biotechnological research and development and is a leading company in this field.

odotettu liikevaihto Takara Bio on 49,46 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Takara Bio on 4,72 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Takara Bio:n hinta-voitto-suhde (P/E) on tällä hetkellä 29,18. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Takara Bio-osakkeen arvostusta.

Takara Bio:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,79. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Takara Bio-osakkeen arvostuskennuslukuna.

Takara Bio:n Eulpool-laatuscore on 3/10.

Takara Bio:n ISIN on JP3460200003. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Takara Bio:n WKN on A0DNGL. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Takara Bio:n ticker on 4974.T. Tämä pörssinoteeraus käytetään Takara Bio-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Takara Bio maksoi osinkoa 17,00 JPY . Tämä vastaa osingontuottoa noin 1,49 %. Tulevien 12 kuukauden aikana Takara Bio odotetaan maksavan osinkoa 34,00 JPY.

Takara Bio:n nykyinen osinkotuotto on 1,49 %.

Takara Bio maksaa osinkoa, joka jaetaan kuukausina , , , .

Takara Bio maksoi osinkoa joka vuosi viimeisten 14 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 34,00 JPY. Tämä vastaa osingontuottoa 2,97 %.

Takara Bio kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Takara Bio:sta päivältä määrässä 17 JPY, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Takara Bio jakoi 42 JPY osinkona.

Takara Bio:n osingot jaetaan valuutassa JPY.